Technical Analysis for CRBU - Caribou Biosciences, Inc.

Grade Last Price % Change Price Change
F 4.63 7.67% 0.33
CRBU closed up 7.67 percent on Friday, March 24, 2023, on 1.23 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Bullish Engulfing Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 7.67%
Lower Bollinger Band Walk Weakness 7.67%
New 52 Week Low Weakness 7.67%
Wide Bands Range Expansion 7.67%
Below Lower BB Weakness 7.67%
Down 3 Days in a Row Weakness 7.67%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 11 hours ago
Rose Above Previous Day's High about 14 hours ago
Up 5% about 14 hours ago
Up 3% about 14 hours ago
Up 2% about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Caribou Biosciences, Inc. Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Hematologic Malignancies Breakthrough Therapy Chimeric Antigen Receptor T Cell CD19 Refractory Acute Myeloid Leukemia T Cells Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

Is CRBU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.19
52 Week Low 4.12
Average Volume 450,939
200-Day Moving Average 8.07
50-Day Moving Average 6.26
20-Day Moving Average 5.35
10-Day Moving Average 4.87
Average True Range 0.35
RSI 31.03
ADX 38.83
+DI 13.01
-DI 34.91
Chandelier Exit (Long, 3 ATRs) 5.23
Chandelier Exit (Short, 3 ATRs) 5.18
Upper Bollinger Bands 6.50
Lower Bollinger Band 4.20
Percent B (%b) 0.19
BandWidth 42.91
MACD Line -0.52
MACD Signal Line -0.46
MACD Histogram -0.0582
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.33
Resistance 3 (R3) 5.28 5.00 5.21
Resistance 2 (R2) 5.00 4.82 5.02 5.17
Resistance 1 (R1) 4.81 4.71 4.91 4.86 5.13
Pivot Point 4.53 4.53 4.58 4.56 4.53
Support 1 (S1) 4.35 4.35 4.44 4.40 4.13
Support 2 (S2) 4.07 4.24 4.09 4.09
Support 3 (S3) 3.88 4.07 4.05
Support 4 (S4) 3.93